Significance of serum TRACP in rheumatoid arthritis

Journal of Bone and Mineral Research

Volumn 23, Issue 8, 2008, Pages 1287-1295

  Janckila, Anthony J ^a,b   Neustadt, David H ^b   Yam, Lung T ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Bone resorption; Inflammation; Macrophage; Osteoclast; Rheumatoid arthritis; TRACP

Indexed keywords

ALKALINE PHOSPHATASE; ANTIBODY; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CARTILAGE GLYCOPROTEIN 39; COLLAGEN TYPE 1; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLYCOPROTEIN GP 39; IMMUNOGLOBULIN M; ISOPROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR; TRACP 5A PROTEIN; TRACP 5B PROTEIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTICLE; BONE DESTRUCTION; CELL COUNT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; OSTEOCLAST; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN VARIANT; RHEUMATOID ARTHRITIS;

ACID PHOSPHATASE; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOARTHRITIS; REGRESSION ANALYSIS;

EID: 47849116207     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.080329     Document Type: Article

References (39)

1. Firestein GF 2003 Evolving concepts of rheumatoid arthritis. Nature 423:356-361.
2. Walsh NC, Crotti TN, Goldring SR, Gravallese EM 2005 Rheumatic diseases: The effects of inflammation on bone. Immunol Rev 208:228-251.
3. Kremers HM, Nicola P, Crowson CS, O'Fallon WM, Gabriel SE 2004 Therapeutic strategies in rheumatoid arthritis over a 40-year period. J Rheumatol 31:2366-2373.
4. Walsh N, Gravallese EM 2004 Bone loss in inflammatory arthritis: Mechanisms and treatment strategies. Curr Opin Rheumatol 16:419-427.
5. Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL 2003 Extra-articular manifestations in rheumatoid arthritis: Incidence trends and risk factors over 46 years. Ann Rheum Dis 62:722-727.
6. Scott DL 2000 Prognostic factors in early rheumatoid arthritis. Rheumatol 39(Suppl 1):24-29.
7. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, Lord JM, Gordon C, Buckley CD, Salmon M 2005 Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 7:R784-R795.
8. Dörner T, Egerer K, Feist E, Burmester GR 2004 Rheumatoid factor revisited. Curr Opin Rheumatol 16:246-253.
9. Avouac J, Gossec L, Dougados M 2006 Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: A systematic literature review. Ann Rheum Dis 65:845-851.
10. Garnero P, Gineyts E, Christgau S, Finck B, Delmas PD 2002 Association of baseline levels of urinary glucosyl-galactosylpyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum 46:21-30.
11. Young-Min S, Cawston T, Marshall N, Coady D, Christgau S, Saxne T, Robins S, Griffiths I 2007 Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 56:3236-3247.
12. Crnkic M, Månsson B, Larsson L, Geborek P, Heinegård D, Saxne T 2003 Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res Ther 5:R181-R185.
13. Vos K, Steenbakkers P, Miltenburg AMM, Bos E, van den Heuvel MW, van Hogezand RA, de Vries RR, Breedveld FC, Boots AM 2000 Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 59:544-548.
14. Sassi ML, Aman S, Hakala M, Luukkainen R, Risteli J 2003 Assay for cross-linked carboxyterminal telopeptide of type I collagen (ICTP) unlike CrossLaps assay reflects increased pathological degradation of type I collagen in rheumatoid arthritis. Clin Chem Lab Med 41:1038-1044.
15. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Ovist P, Delmas PD, Foged NT, Delaissé JM 2003 The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18:859-867.
16. Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimäki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievänen H, Vuori I, Väänänen HK, Halleen JM 2005 Serum TRACP 5b is a useful marker for monitoring alendronate treatment: Comparison with other markers of bone turnover. J Bone Miner Res 20:1804-1812.
17. Janckila AJ, Takahashi K, Sun SZ, Yam LT 2001 Tartrate-resistant acid phosphatase isoform 5b as a marker for osteoclastic activity. Clin Chem 47:74-80.
18. Halleen JM, Ylipahkala H, Alatalo SL, Janckila AJ, Heikkinen JE, Suominen H, Cheng S, Väänänen HK 2002 Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int 71:20-25.
19. Janckila AJ, Neustadt DH, Nakasato YR, Halleen JM, Hentunen T, Yam LT 2002 Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis. Clin Chim Acta 320:49-58.
20. Janckila AJ, Parthasarathy RN, Parthasarathy LK, Seelan RS, Hsueh YC, Rissanen J, Alatalo SL, Halleen JM, Yam LT 2005 Properties and expression of human tartrate-resistant acid phosphatase isoform 5a by monocvte-derived cells. J Leukoc Biol 77:209-218.
21. Chao CY, Lee SH, Chen MM, Neustadt DH, Chaudhry UA, Yam LT, Janckila AJ 2005 Development of immunoassays for serum tartrate-resistant acid phosphatase isoform 5a. Clin Chim Acta 359:132-140.
22. Janckila AJ, Slone SP, Lear SC, Martin A, Yam LT 2007 Tartrate-resistant acid phospahtase as an immunohistochemical marker for inflammatory macrophages. Am J Clin Pathol 127:556-566.
23. Ljusberg J, Wang Y, Lang P, Norgard M, Dodds R, Hultenby K, Ek-Rylander B, Andersson G 2005 Proteolytic excision of a repressive loop domain in tartrate-resistant acid phosphatase by cathepsin K in osteoclasts. J Biol Chem 280:28370-28381.
24. Janckila AJ, Simons RM, Yam LT 2004 Alternate immunoassay for tartrate-resistant acid phosphatase isoform 5b using the fluorogenic substrate naphthol ASBI-phosphate and heparin. Clin Chim Acta 347:157-167.
25. Halleen JM, Karp M, Viloma S, Laaksonen P, Hellman J, Käkönen SM, Stepan JJ, Holmes S, Väänänen HK, Pettersson K 1999 Two-site immunoassays for osteoclastic tartrate-resistant acid phosphatase based on characterization of six monoclonal antibodies. J Bone Miner Res 14:464-469.
26. Nakanishi M, Yoh K, Miura T, Ohashi T, Rai SK, Uchida K 2000 Development of a kinetic assay for band 5b tartrate-resistant acid phosphatase activity in serum. Clin Chem 46:469-473.
27. Miyazaki T, Matsunaga T, Miyazaki S, Hokari S, Komoda T 2002 Characterization of four monoclonal antibodies to recombinant human tartrate-resistant acid phosphatase. Hybrid Hybridomics 21:191-195.
28. Ohashi T, Igarishi Y, Mochizuki Y, Miura T, Inaba N, Katayama K, Tomonaga T, Nomura F 2007 Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b. Clin Chim Acta 376:205-212.
29. Mose S, Menzel C, Kurth AA, Obert K, Breidert I, Borowsky K, Böttcher HD 2003 Tartrate-resistant acid phosphatase 5b as a serum marker of bone metabolism in cancer patients. Anti-cancer Res 23:2783-2788.
30. Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A, Pettersson K, Väänänen HK, Akesson K, Obrant KJ 2004 Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19:386-393.
31. Tsai S-H, Chen C-Y, Ku C-H, Janckila AJ, Yam LT, Yu J-C, Chuang KW, Chao TY 2007 The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis. Mayo Clin Proc 82:917-926.
32. Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Väänänen HK, Halleen JM 2004 Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schönberg disease (Type II autosomal dominant osteopetrosis). Clin Chem 50:883-890.
33. Gravallese EM, Harada Y, Wang JT, Corn AH, Thornhill TS, Goldring SR 1998 Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 152:943-951.
34. Hayman AR, Bune AJ, Bradley JB, Rashbass J, Cox TM 2000 Osteoclastic tartrate-resistant acid phosphatase (Acp5): Its localization to dendritic cells and diverse murine tissues. J Histochem Cytochem 48:219-228.
35. Lång P, Andersson G 2005 Differential expression of monomeric and proteolytically processed forms of tartrate-resistant acid phosphatase in rat tissues. Cell Mol Life Sci 62:905-918.
36. Tsuboi H, Matsui Y, Hayashida K, Yamane S, MaedaTanimura M, Nampei A, Hashimoto J, Suzuki R, Yoshikawa H, Ochi T 2003 Tartrate-resistant acid phosphatase (TRAP) positive cells in rheumatoid synovium may induce the destruction of articular cartilage. Ann Rheum Dis 62:196-203.
37. Lukkainen R, Talonen R, Kaarela K, Merilahti-Palo R, Rintala E 1990 Synovial fluid acid phosphatase in seropositive and seronegative arthritides. Clin Exp Rheumatol 8:63-65.
38. Ziff M 1990 The rheumatoid nodule. Arthritis Rheum 33:761-767.
39. Wikaningrum R, Highton J, Parker A, Coleman M, Hessian PA, Roberts-Thomson PJ, Ahern MJ, Smith MD 1998 Pathogenic mechanisms in the rheumatoid nodule. Comparison of proinflammatory cytokine production and cell adhesion molecule expression in rheumatoid nodules and synovial membranes from the same patient. Arthritis Rheum 41:1783-1797.